Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

Präklinische Studie Zur Etablierung Einer Immuntherapie für Das Nebennierenrindenkarzinom - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00457587

Enrollment

150

Registered

2007-04-06

Start date

2005-09-01

Completion date

2030-12-01

Last updated

2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenocortical Carcinoma, Cushing's Syndrome

Brief summary

Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* patients with histological proven adrenocortical carcinoma * healthy persons as control group * Life expectancy \> 6 months

Exclusion criteria

* autoimmune diseases * severe clinical condition

Design outcomes

Primary

Measure	Time frame
To find reasonable antigens for a vaccination therapy in ACC	day of blood sampling
To investigate the role of tumor-induced suppression in ACC	NA, in vitro study

Countries

Germany

Contacts

PRINCIPAL_INVESTIGATORMartin Fassnacht, MD

University of Wuerzburg

Outcome results